Key Highlights

  • Shares closed at $1.11 at last closing, up 4.72%, in penny-stock territory.
  • Second-quarter 2026 results showed no revenue, a net loss of about $1.5 million for the quarter, and cash of roughly $8.7 million.
  • The company raised about $4.5 million through Warrant exercises in June, with substantial warrants outstanding that pose dilution risk.
  • Creative Medical Technology Holdings is a clinical-stage regenerative-medicine company developing stem-cell and immunotherapy candidates, including a Fast Track-designated cell-therapy trial in type 1 diabetes.

Penny stock Creative Medical Technology Holdings (NASDAQ:CELZ) is a clinical-stage regenerative-medicine and biotechnology company developing stem-cell and immunotherapy candidates across areas such as type 1 diabetes and orthopedics. Shares closed at $1.11 at last closing, up 4.72%.

As a pre-revenue micro-cap, its results depend on the progress of its clinical programs, its cash position and burn, and its ability to raise capital, so it is highly speculative and dependent on external financing, with its future tied to binary trial outcomes.

Latest Developments

In its second-quarter 2026 results, Creative Medical Technology reported no revenue, a net loss of about $1.5 million for the quarter, and cash of roughly $8.7 million, having raised about $4.5 million through warrant exercises in June, with substantial warrants outstanding that pose dilution risk. It pointed to progress in its clinical programs, including a Fast Track-designated cell-therapy trial in type 1 diabetes. Investors should verify the net loss and cash burn, the cash position and runway, and clinical milestones directly from SEC filings, recognizing that the company is pre-revenue, loss-making, and reliant on external financing.

Financial and Business Position

As a pre-revenue clinical-stage micro-cap, Creative Medical Technology's financial position is defined by its lack of revenue, its ongoing losses and cash burn, and its reliance on dilutive financing. Investors should focus on the net loss and cash burn, the cash position and runway, and clinical progress.

Stock-Market Context

CELZ shares closed at $1.11 at last closing, up 4.72%, keeping the stock in penny territory. The stock is a speculative micro-cap whose shares are highly volatile and sensitive to clinical news, cash, and financing, and the risk of substantial loss and dilution is significant.

What Investors Should Watch

Watch the net loss and cash burn, the cash position and runway, warrant and financing activity that dilutes shareholders, and clinical progress such as data from its type 1 diabetes program. Positive clinical readouts backed by adequate, less dilutive funding would be the clearest factors that could reverse the momentum.